Stock Taper
SCREENER COMPARE ANY 2 STOCKS
DNLI
DENALI THERAPEUTICS INC.
NASDAQ
$22.80
▼ DOWN 0.22% (-0.05)

KEY STATISTICS

Market Cap$3.57 B
52w High$27.30
52w Low$12.58
Dividend Yield—
Frequency—
P/E-7.92
Volume1.73M
Shares Out.158.71M

COMPANY

LEADERSHIP

Ryan J. Watts
CHIEF EXECUTIVE
Ryan J. Watts

COMPENSATION 2026

Salary$718,000
Stock Awards$1,151,867
Incentive Plan Pay$0
All Other Comp.$24,939
Total$4,751,515

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 8, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
503

PRICE TARGET

Target High$41.00
Target Low$26.00
Target Median$34.00
Target Consensus$33.67

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$12.23M
NOV
5
THU

PRICE

$22.80 ▼ DOWN 0.22% (−$0.05)
$22.50$22.65$22.809:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM22.80

About Denali Therapeutics Inc.

https://www.denalitherapeutics.com ↗

Denali Therapeutics Inc. is a biopharmaceutical company developing therapies for neurodegenerative diseases, with clinical-stage candidates for Parkinson's, ALS, Hunter syndrome, and lupus, and collaborations with major pharma and research organiz...

INDUSTRY

Biotechnology

A PRODUCT DENALI THERAPEUTICS INC. IS KNOWN FOR

Tividenofusp alfa
Tividenofusp alfa

An investigational enzyme replacement therapy for Hunter syndrome (MPS II) using Denali's Transport Vehicle to cross the blood-brain barrier, currently under FDA review for accelerated approval and a key focus for the company's commercialization.

COMPETITORS

COMPETITOR
ALEC COMPARE
BIIB COMPARE
IONS COMPARE
PRTA COMPARE
RGNX COMPARE

Revenue by Products

IconPRODUCTQ3-2020Q4-2020Q1-2021Q2-2021
Alzheimers Disease Services$3.4M $0 ▼$3.4M ▲$3.4M

ETFS HOLDING THIS STOCK

ETFS HOLDING
154
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.00% · 4.3M
XSU.TO
0.11% · 3.8M
XBI
0.73% · 3.7M
TCAF
0.35% · 1.3M
SCHA
0.07% · 715.0K
DFMC
0.15% · 506.5K
SBIO
2.01% · 214.2K
PRFZ
0.16% · 202.2K
XRSU.L
0.11% · 129.7K
LABU
0.48% · 123.3K
FESM
0.04% · 107.9K
RSSL
0.11% · 70.5K
FDG
0.44% · 70.4K
BBP
1.28% · 67.6K
BBSC
0.12% · 38.7K
JHSC
0.12% · 37.6K
MNTL
1.98% · 15.2K
GSSC
0.02% · 11.7K
AVUS
0.00% · 10.5K
TILT
0.01% · 10.4K
NIXT
0.52% · 9.9K
RFLR
0.15% · 6.2K
URTY
0.04% · 5.8K
BKSE
0.14% · 5.5K
STXK
0.13% · 4.9K
FTKI
0.29% · 3.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
68.57%
HOLDERS
404
TOP 12 OF 404 · RANKED BY POSITION SIZE
T. Rowe Price Investment Management, Inc.
16.2M sh · $416.12M
Blackrock, Inc.
14.0M sh · $360.76M
Blackrock Inc.
13.2M sh · $305.91M
Vanguard Group Inc
13.1M sh · $215.59M
Baillie Gifford & Co
12.1M sh · $231.68M
State Street Corp
7.0M sh · $181.31M
Temasek Holdings (Private) Ltd
7.0M sh · $115.78M
Fmr LLC
6.3M sh · $92.06M
Ubs Asset Management Americas Inc
5.5M sh · $79.35M
Norges Bank
5.1M sh · $84.52M
Capital Research Global Investors
4.8M sh · $69.13M
Price T Rowe Associates Inc /Md/
4.6M sh · $66.33M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Watts Ryan J.
Sale · 32.2K shares
2026-08-12
★
OFFICER: COFO AND SECRETARY
Schuth Alexander O.
Sale · 2.9K shares
2026-08-11
★
DIRECTOR
BAKER BROS. ADVISORS LP
Purchase · 6.4K shares
2026-06-03
★
DIRECTOR
Van Hauwermeiren Timothy
Purchase · 19.2K shares
2026-06-03

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 7
OVERWEIGHT 3
OUTPERFORM 3
13 GRADES IN THE LAST 12 MONTHS
B. Riley Securities BUY UBS BUY Morgan Stanley OVERWEIGHT Deutsche Bank BUY BTIG BUY Wedbush OUTPERFORM Leerink Partners OUTPERFORM Baird OUTPERFORM

SECTORS PEERS

PEERPRICE
IBRX$7.97COMPARE
LQDA$68.81COMPARE
COGT$34.95COMPARE
RCUS$29.91COMPARE
BEAM$29.13COMPARE
VRDN$22.99COMPARE
AGIO$33.38COMPARE
RXRX$3.39COMPARE